DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
October 31 2022 - 8:32AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company focused on developing novel treatments
for neurological disorders and kidney diseases, today announced
that Rick Pauls, its President and CEO, will present a corporate
overview at the Credit Suisse 31st Annual Healthcare Conference,
which will take place November 8 – 10, 2022 in Rancho Palos Verdes,
California.
Mr. Pauls is scheduled to present at 8:35 a.m. Eastern Time on
November 9, 2022. In addition to the presentation, Mr. Pauls will
be available for one-on-one investor meetings throughout the
conference. Investors that are interested in arranging a meeting
should contact their Credit Suisse representative.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases. Its lead candidate, DM199,
is the first pharmaceutically active recombinant (synthetic) form
of the KLK1 protein, an established therapeutic modality for the
treatment of acute ischemic stroke and chronic kidney disease. For
more information visit the Company’s website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221031005095/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Historical Stock Chart
From Aug 2024 to Sep 2024
DiaMedica Therapeutics (NASDAQ:DMAC)
Historical Stock Chart
From Sep 2023 to Sep 2024